|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHMP4A |
Gene summary for CHMP4A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHMP4A | Gene ID | 29082 |
| Gene name | charged multivesicular body protein 4A | |
| Gene Alias | C14orf123 | |
| Cytomap | 14q12 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | Q9BY43 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29082 | CHMP4A | LZE2T | Human | Esophagus | ESCC | 1.01e-05 | 7.12e-01 | 0.082 |
| 29082 | CHMP4A | LZE4T | Human | Esophagus | ESCC | 4.91e-30 | 8.18e-01 | 0.0811 |
| 29082 | CHMP4A | LZE5T | Human | Esophagus | ESCC | 4.13e-15 | 9.58e-01 | 0.0514 |
| 29082 | CHMP4A | LZE7T | Human | Esophagus | ESCC | 3.71e-10 | 5.25e-01 | 0.0667 |
| 29082 | CHMP4A | LZE8T | Human | Esophagus | ESCC | 4.50e-15 | 4.37e-01 | 0.067 |
| 29082 | CHMP4A | LZE20T | Human | Esophagus | ESCC | 1.44e-09 | 3.93e-01 | 0.0662 |
| 29082 | CHMP4A | LZE22D1 | Human | Esophagus | HGIN | 2.47e-04 | 2.84e-01 | 0.0595 |
| 29082 | CHMP4A | LZE22T | Human | Esophagus | ESCC | 1.27e-06 | 5.37e-01 | 0.068 |
| 29082 | CHMP4A | LZE24T | Human | Esophagus | ESCC | 8.95e-36 | 8.39e-01 | 0.0596 |
| 29082 | CHMP4A | LZE21T | Human | Esophagus | ESCC | 5.20e-09 | 7.18e-01 | 0.0655 |
| 29082 | CHMP4A | LZE6T | Human | Esophagus | ESCC | 2.15e-14 | 6.26e-01 | 0.0845 |
| 29082 | CHMP4A | P1T-E | Human | Esophagus | ESCC | 2.23e-11 | 6.59e-01 | 0.0875 |
| 29082 | CHMP4A | P2T-E | Human | Esophagus | ESCC | 1.81e-22 | 3.49e-01 | 0.1177 |
| 29082 | CHMP4A | P4T-E | Human | Esophagus | ESCC | 2.11e-31 | 6.62e-01 | 0.1323 |
| 29082 | CHMP4A | P5T-E | Human | Esophagus | ESCC | 2.56e-42 | 8.12e-01 | 0.1327 |
| 29082 | CHMP4A | P8T-E | Human | Esophagus | ESCC | 8.71e-38 | 7.39e-01 | 0.0889 |
| 29082 | CHMP4A | P9T-E | Human | Esophagus | ESCC | 6.45e-20 | 4.54e-01 | 0.1131 |
| 29082 | CHMP4A | P10T-E | Human | Esophagus | ESCC | 4.31e-33 | 5.74e-01 | 0.116 |
| 29082 | CHMP4A | P11T-E | Human | Esophagus | ESCC | 1.38e-11 | 4.53e-01 | 0.1426 |
| 29082 | CHMP4A | P12T-E | Human | Esophagus | ESCC | 1.09e-56 | 9.86e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00719858 | Thyroid | PTC | multivesicular body sorting pathway | 27/5968 | 37/18723 | 3.42e-07 | 5.75e-06 | 27 |
| GO:000703210 | Thyroid | PTC | endosome organization | 48/5968 | 82/18723 | 5.65e-07 | 9.04e-06 | 48 |
| GO:00002818 | Thyroid | PTC | mitotic cytokinesis | 43/5968 | 71/18723 | 5.93e-07 | 9.47e-06 | 43 |
| GO:007259918 | Thyroid | PTC | establishment of protein localization to endoplasmic reticulum | 31/5968 | 46/18723 | 8.06e-07 | 1.24e-05 | 31 |
| GO:000004514 | Thyroid | PTC | autophagosome assembly | 54/5968 | 99/18723 | 2.46e-06 | 3.22e-05 | 54 |
| GO:004504716 | Thyroid | PTC | protein targeting to ER | 28/5968 | 42/18723 | 3.83e-06 | 4.80e-05 | 28 |
| GO:190503713 | Thyroid | PTC | autophagosome organization | 55/5968 | 103/18723 | 4.75e-06 | 5.79e-05 | 55 |
| GO:190211516 | Thyroid | PTC | regulation of organelle assembly | 88/5968 | 186/18723 | 7.41e-06 | 8.65e-05 | 88 |
| GO:004532414 | Thyroid | PTC | late endosome to vacuole transport | 19/5968 | 25/18723 | 7.43e-06 | 8.65e-05 | 19 |
| GO:001906816 | Thyroid | PTC | virion assembly | 24/5968 | 35/18723 | 9.08e-06 | 1.03e-04 | 24 |
| GO:000091019 | Thyroid | PTC | cytokinesis | 82/5968 | 173/18723 | 1.37e-05 | 1.47e-04 | 82 |
| GO:190121518 | Thyroid | PTC | negative regulation of neuron death | 95/5968 | 208/18723 | 2.01e-05 | 2.04e-04 | 95 |
| GO:00325115 | Thyroid | PTC | late endosome to vacuole transport via multivesicular body sorting pathway | 14/5968 | 17/18723 | 2.62e-05 | 2.56e-04 | 14 |
| GO:00000705 | Thyroid | PTC | mitotic sister chromatid segregation | 79/5968 | 168/18723 | 2.78e-05 | 2.71e-04 | 79 |
| GO:00070595 | Thyroid | PTC | chromosome segregation | 146/5968 | 346/18723 | 2.99e-05 | 2.87e-04 | 146 |
| GO:00008196 | Thyroid | PTC | sister chromatid segregation | 92/5968 | 202/18723 | 3.07e-05 | 2.94e-04 | 92 |
| GO:00069977 | Thyroid | PTC | nucleus organization | 65/5968 | 133/18723 | 3.16e-05 | 3.01e-04 | 65 |
| GO:00325068 | Thyroid | PTC | cytokinetic process | 25/5968 | 39/18723 | 3.50e-05 | 3.30e-04 | 25 |
| GO:00066126 | Thyroid | PTC | protein targeting to membrane | 64/5968 | 131/18723 | 3.67e-05 | 3.41e-04 | 64 |
| GO:00397029 | Thyroid | PTC | viral budding via host ESCRT complex | 16/5968 | 21/18723 | 3.87e-05 | 3.56e-04 | 16 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa032502 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0325011 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa032508 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0325013 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
| hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0325022 | Oral cavity | LP | Viral life cycle - HIV-1 | 32/2418 | 63/8465 | 1.55e-04 | 9.08e-04 | 5.86e-04 | 32 |
| hsa0421714 | Oral cavity | LP | Necroptosis | 59/2418 | 159/8465 | 1.15e-02 | 3.91e-02 | 2.52e-02 | 59 |
| hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHMP4A | SNV | Missense_Mutation | rs575738905 | c.346N>A | p.Glu116Lys | p.E116K | Q9BY43 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHMP4A | SNV | Missense_Mutation | novel | c.618N>T | p.Glu206Asp | p.E206D | Q9BY43 | protein_coding | tolerated(0.44) | possibly_damaging(0.707) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CHMP4A | SNV | Missense_Mutation | c.398N>A | p.Arg133His | p.R133H | Q9BY43 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CHMP4A | SNV | Missense_Mutation | c.569N>A | p.Ser190Tyr | p.S190Y | Q9BY43 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CHMP4A | SNV | Missense_Mutation | novel | c.341N>T | p.Arg114Ile | p.R114I | Q9BY43 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| CHMP4A | SNV | Missense_Mutation | novel | c.341N>T | p.Arg114Ile | p.R114I | Q9BY43 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CHMP4A | SNV | Missense_Mutation | c.53T>C | p.Met18Thr | p.M18T | Q9BY43 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHMP4A | SNV | Missense_Mutation | c.300N>T | p.Lys100Asn | p.K100N | Q9BY43 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHMP4A | SNV | Missense_Mutation | novel | c.563N>T | p.Ala188Val | p.A188V | Q9BY43 | protein_coding | tolerated(0.08) | possibly_damaging(0.836) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHMP4A | SNV | Missense_Mutation | c.569C>T | p.Ser190Phe | p.S190F | Q9BY43 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |